The FDA has approved Prograf (tacrolimus, from Astellas) in conjunction with mycophenolate mofetil (MMF) for the prevention of organ rejection in kidney transplant recipients. This approval was based ...
Bottles of two medications that prevent the body's rejection of transplanted organs were recalled because the capsules may be empty. Astellas Pharma US, Inc. announced this week it is voluntarily ...
Add Yahoo as a preferred source to see more of our stories on Google. Two drugs have been recalled because their capsules might be empty — and the consequences could be deadly. Astellas Pharma’s ...
Prograf Granules is a new treatment option for patients who may have difficulty swallowing the capsule formulation. The new formulation received approval from the Food and Drug Administration (FDA) in ...
NORTHBROOK, Ill., July 20, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the U.S. Food and Drug Administration (FDA) has ...
Two drugs have been recalled because their capsules might be empty — and the consequences could be deadly. Astellas Pharma’s Prograf gets prescribed after heart, liver, kidney or lung transplants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results